MedTrace Logo

Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney

NCT00106561 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to determine which combination of the tablets ramipril, irbesartan or spironolactone is best to lower protein leakage from the kidney.

Conditions

Interventions

DRUG

Spironolactone

DRUG

Irbesartan

Sponsors & Collaborators

  • Melbourne Health

    lead OTHER

Principal Investigators

  • Gavin G Becker, MBBS MD · Director Department of Nephrology, The Royal Melbourne Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Completion
2004-09-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00106561 on ClinicalTrials.gov